Comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 vs 11p15 4 Microduplication Syndrome C4749508
Clinical comparison between 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete CN042980 and 11p15 4 Microduplication Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
A rare enzyme deficiency affecting hormone production, leading to low sex hormones and elevated blood pressure. Lifelong hormone replacement therapy is typically needed. Ongoing medical monitoring helps manage associated health concerns.
11p15 4 Microduplication Syndrome C4749508
A rare genetic disorder involving duplication of material on chromosome 11, leading to varied developmental features. Requires individualized medical assessment.
6 comparison axes
Onset
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
0-null
11p15 4 Microduplication Syndrome C4749508
0-null
Onset patterns differ
Severity
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
severe
11p15 4 Microduplication Syndrome C4749508
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
Chronic
11p15 4 Microduplication Syndrome C4749508
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
No
11p15 4 Microduplication Syndrome C4749508
No
Different transmission
Body System
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
11p15 4 Microduplication Syndrome C4749508
congenital
Same/different system
Category
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
endocrine
11p15 4 Microduplication Syndrome C4749508
genetic
Different category
Bottom line
17-alpha-hydroxylase-17-20-lyase-deficiency-combined-complete-CN042980 and 11p15-4-microduplication-syndrome-C4749508 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | 11p15 4 Microduplication Syndrome C4749508 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension may occur from altered adrenal steroid production; timing is not established. | Hypertension is not described as a defining feature. | High |
| Sex-hormone effects | Low sex-hormone production may affect puberty or genital development; findings vary. | No specific sex-hormone pattern is established in the source. | High |
| Development | Primarily described as an endocrine disorder, not a duplication syndrome. | Duplication at 11p15.4 may cause varied developmental features. | Moderate |
When to favor each condition
Choose 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 when
Hypertension with suspected low sex hormones
This pattern aligns better with the described enzyme deficiency.
Moderate
Abnormal steroid pathway is suspected
Endocrine and CYP17A1-related evaluation is more relevant.
Moderate
Hormone replacement is being considered
The source says replacement is typically needed, but treatment must be clinician-directed.
High
Choose 11p15 4 Microduplication Syndrome C4749508 when
Testing shows an 11p15.4 duplication
A confirmed duplication directly supports the genetic condition.
High
Developmental features occur without an endocrine pattern
This fits the sparse congenital description better, but is not diagnostic alone.
Low
The main question is genomic or familial
The condition is categorized as genetic and congenital rather than enzymatic.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980 | 11p15 4 Microduplication Syndrome C4749508 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | May suggest disordered adrenal or gonadal steroid production; no cutoff is supplied. | No characteristic steroid abnormality is established. | Abnormal results require specialist interpretation and are not diagnostic alone. |
| Genetic testing | CYP17A1-related testing may be considered when clinically indicated. | Chromosomal microarray or genomic testing may detect an 11p15.4 duplication. | The appropriate test depends on the suspected mechanism. |
| Clinical assessment | Blood pressure and pubertal or genital findings need monitoring. | Developmental and congenital assessment is central. | Clinical findings support evaluation but do not establish either diagnosis alone. |
Prognosis comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Complete Cn042980
- Outcome
- Often a chronic endocrine condition requiring long-term hormone care; exact outcome is not established.
- Factors
- Blood-pressure control, appropriate replacement, and specialist follow-up.
11p15 4 Microduplication Syndrome C4749508
- Outcome
- A chronic genetic condition with variable developmental impact; prognosis is not established.
- Factors
- Duplication content, developmental findings, and available supportive care.
Time frame: Both may require lifelong follow-up; specific milestones are not established.
Early recognition, individualized monitoring, and avoidance of unsupported assumptions.
Complications comparison
| Complication | Presentation |
|---|---|
| Blood-pressure effects | Possible when mineralocorticoid-related hypertension is present. Not established from the supplied description. Do not assume cardiovascular complications without clinical evidence. |
| Pubertal or reproductive effects | Low sex hormones may affect puberty or fertility; severity varies. No specific reproductive complication is described. Specialist assessment is required before drawing conclusions. |
| Developmental complications | Not described as the primary feature. Varied developmental features may occur. Support needs should be individualized because the phenotype is not fully established. |
Patient education highlights
- HighDifferent conditions
These are separate rare conditions with endocrine and chromosomal mechanisms, respectively.
- HighSpecialist diagnosis
A label should not be based on symptoms alone; genetic or endocrine confirmation may be needed.
- MediumTreatment safety
Do not start, stop, or adjust hormones without a clinician; no dose is established here.